Gene Predictis®, a Swiss precision medicine company, announces the closing of its first financing round. The company has raised CHF 0.5 million from a strategic investor that is a major player in the Swiss health care ecosystem.
The proceeds will be used to support marketing and commercialization in Switzerland of its leading product, Pill Protect®, as well as for the CE-IVD labelling of Pill Protect® to assure its timely launch on the EU market. Pill Protect® is an innovative medical test that uses genetic data to identify women at risk of developing blood clots (thrombosis) when using contraceptive pills. The test was launched in Switzerland in mid-September 2015 and has received very promising initial market acceptance.
The closing of this initial investment follows the successful achievement of a series of milestones in 2015, including successful clinical validation study for Pill Protect®, Pill Protect® patent filing and the launch of the product on the Swiss market.
Gene Predictis® pursues an additional investment with a financial partner mainly to fund the launch of Pill Protect® and Cypass®, another strategic product, in markets outside of Switzerland.